Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Global Health. 2018;6(7):e744–57.

Article  PubMed  Google Scholar 

Dhoubhadel BG, Morimoto K. Prevention of pneumococcal diseases: the challenge remains. Lancet Global Health. 2022;10(10):e1375–6.

Article  PubMed  CAS  Google Scholar 

Kumar P, Neyazi A, Rillera Marzo R, Augusto Guimaraes C, Barboza J, Abu Serhan J. H, Mycoplasma pneumoniae returns: understanding its spread and growing impact. Evid. 2024;2(1).

Savoy M, Pneumococcal Vaccine MSD, Manual Professional, Edition. MSD Manual; 2024 [updated 2024/04. https://www.msdmanuals.com/en-in/professional/infectious-diseases/immunization/pneumococcal-vaccine

Lawrence H, Pick H, Baskaran V, Daniel P, Rodrigo C, Ashton D, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLoS Med. 2020;17(10):e1003326.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chan T-C, Hung IF-N, Luk JK-H, Shea Y-F, Chan FH-W, Woo PC-Y, Chu L-W. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1). J Am Med Dir Assoc. 2012;13(8):698–703.

Article  PubMed  Google Scholar 

Hsieh M-J, Tsai Y-H, Chang C-J, Wen Y-W, Hu H-C, Chao Y-N, et al. The efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing pneumonia and invasive pneumococcal disease in the elderly aged 75 years and older in Taiwan. Chest. 2013;144(4):254A.

Article  Google Scholar 

Hung C-C, Chen M-Y, Hsieh S-M, Hsiao C-F, Sheng W-H, Chang S-C. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine. 2004;22(15–16):2006–12.

Article  PubMed  CAS  Google Scholar 

Inoue S, Watanuki Y, Kaneko T, Sato T, Miyazawa N, Kaneko T, et al. Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study. BMJ open. 2011;1(1):e000105.

Article  PubMed  PubMed Central  Google Scholar 

Kolditz M, Schmitt J, Pletz MW, Tesch F. Impact of pneumococcal polysaccharide vaccine on incidence and mortality after pneumonia in adults aged ≥ 60 years—a population-based retrospective cohort study. Clin Microbiol Infect. 2018;24(5):500–4.

Article  PubMed  CAS  Google Scholar 

Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010;340.

Ochoa-Gondar O, Vila-Corcoles A, Ansa X, Rodriguez-Blanco T, Salsench E, de Diego C, et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine. 2008;26(16):1955–62.

Article  PubMed  CAS  Google Scholar 

Belmonti S, Rossetti B, Modica S, Paglicci L, Borghetti A, Ciccullo A, et al. Long-term serological response to 13-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in HIV-infected adults. Infect Dis Therapy. 2019;8:453–62.

Article  Google Scholar 

Ravichandran S, Erra-Diaz F, Karakaslar OE, Marches R, Kenyon-Pesce L, Rossi R, et al. Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults. Nat Immunol. 2024;25(2):316–29.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bukhanova D, Sergeeva M, Belov B, Tarasova G, Cherkasova M, Muraviev YA, et al. Immunogenicity and efficiency of a 23-valent pneumococcal vaccine in patients with rheumatoid arthritis: results of a 5-year follow up study. Mod Rheumatol J. 2018;12(4):85–8.

Article  Google Scholar 

Shimbashi R, Suzuki M, Chang B, Watanabe H, Tanabe Y, Kuronuma K, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan, 2013–2017. Emerg Infect Dis. 2020;26(10):2378.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Azuma M, Oishi K, Akeda Y, Morino S, Motoki Y, Hanibuchi M, Nishioka Y. Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: comparison of booster effects based on intervals of 0.5 and 1.0 year. Vaccine. 2023;41(5):1042–9.

Article  PubMed  CAS  Google Scholar 

Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernández M, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006;61(3):189–95.

Article  PubMed  CAS  Google Scholar 

Hsieh M-J, Yu C-C, Hu H-C, Thai Y-H. No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure. Eur Respiratory Soc; 2016.

Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, de Diego-Cabanes C, Hospital-Guardiola I, Jariod-Pamies M, Group ER. Evaluating the clinical effectiveness of pneumococcal vaccination in preventing myocardial infarction: the CAPAMIS study, three-year follow-up. Vaccine. 2014;32(2):252–7.

Article  PubMed  CAS  Google Scholar 

Verma R, Khanna P. Pneumococcal conjugate vaccine: a newer vaccine available in India. Hum Vaccines Immunotherapeutics. 2012;8(9):1317–20.

Article  Google Scholar 

Wasserman M, Chapman R, Lapidot R, Sutton K, Dillon-Murphy D, Patel S, et al. Twenty-year public health impact of 7-and 13-valent pneumococcal conjugate vaccines in US children. Emerg Infect Dis. 2021;27(6):1627.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.

Shabil M, Khatib MN, Banda GT, Zahiruddin QS, Ballal S, Bansal P, et al. Effectiveness of early Anakinra on cardiac function in children with multisystem inflammatory syndrome of COVID-19: a systematic review. BMC Infect Dis. 2024;24(1):847.

Article  PubMed  PubMed Central  Google Scholar 

Shabil M, Khatib MN, Zahiruddin QS, Rekha M, Kaur M, Rani B, et al. Dengue infection during pregnancy and adverse birth outcomes: a systematic review and Meta-analysis. Rev Med Virol. 2024;34(5):e2582.

Article  PubMed  Google Scholar 

Langan D, Higgins JP, Jackson D, Bowden J, Veroniki AA, Kontopantelis E, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta‐analyses. Res Synthesis Methods. 2019;10(1):83–98.

Article  Google Scholar 

Gandhi AP, Shamim MA, Padhi BK. Steps in undertaking meta-analysis and addressing heterogeneity in meta-analysis. Evid. 2023;1(1):44–59.

Google Scholar 

Shabil M, Yadav A, Shamim MA, Ahmed M, Satapathy P, Zaidan AA, et al. Prevalence of hepatitis B and C infections among HIV-positive men who have sex with men: a systematic review and meta‐analysis. Health Sci Rep. 2024;7(6):e2206.

Article  PubMed  PubMed Central  Google Scholar 

Shabil M, Bushi G, Khatib MN. A commentary on psychological health among healthcare professionals during COVID-19 pandemic: an updated meta-analysis. Indian J Psychiatry. 2024;66(8):763–4.

Article  PubMed  PubMed Central  Google Scholar 

IntHout J, Ioannidis JP, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ open. 2016;6(7):e010247.

Article  PubMed  PubMed Central  Google Scholar 

Pandey P, Shabil M, Bushi G. Comment on Sodium fluorescein and 5-aminolevulinic acid fluorescence-guided biopsy in brain lesions: a systematic review and meta-analysis. J Neurooncol. 2024:1–2.

Wen X, Thomas MA, Liu L, Moe AA, Duong PH, Griffiths ME, Munlyn AL. Association between maternal e-cigarette use during pregnancy and low gestational weight gain. Int J Gynaecol Obstet. 2023;162(1):300–8.

Article  PubMed  PubMed Central  Google Scholar 

French N, Nakiyingi J, Carpenter L, Lugada E, Watera C, Moi K, et al. 23–valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355(9221):2106–11.

Article  PubMed  CAS  Google Scholar 

Hyun H, Jang A-Y, Suh JW, Bae I-G, Choi WS, Seo YB et al. Community-acquired pneumococcal pneumonia in highly vaccinated Population: analysis by Serotypes, Vaccination Status, and Underlying Medical conditions. J Korean Med Sci. 2023;38(42).

Ihara H, Kikuchi K, Taniguchi H, Fujita S, Tsuruta Y, Kato M, et al. 23-valent pneumococcal polysaccharide vaccine improves survival in dialysis patients by preventing cardiac events. Vaccine. 2019;37(43):6447–53.

Article  PubMed  CAS  Google Scholar 

Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis. 2010;51(1):15–22.

Article  PubMed  Google Scholar 

Örtqvist Å, Hedlund J, Burman L-Å, Elbel E, Höfer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet. 1998;351(9100):399–403.